Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) will present additional clinical data from the recently completed PRIME study on Gemini at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego.
Presented results reportedly show normalization of the hyperinflammatory state in stage 3–4 CKD patients and restoration of immunocompetence. Presenter: Robin Marsden, SVP Biology. Date/time: Sunday, March 29, 2026, 5:30–7:30 PM PT. Location: Manchester Grand Hyatt, San Diego.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, REVB declined 0.57%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $31K from the company's valuation, bringing the market cap to $5M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Two biotech peers in momentum scans, including SPRC at -9.38% and ELAB at -6.97%, were moving down with a median move of -8.2%, suggesting broader sector pressure rather than REVB-specific trading.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Inducement grant | Neutral | +0.0% | Inducement grant of 90,000 RSUs under Nasdaq Listing Rule 5635(c)(4). |
| Jan 07 | GMP manufacturing | Positive | -1.1% | Initiation of GMP manufacturing of GEMINI and placebo for later-stage trials. |
| Dec 01 | Special meeting quorum | Positive | +0.1% | Quorum reached for December 3, 2025 Special Meeting and regulatory progress update. |
| Nov 20 | Clinical update | Positive | -0.5% | End-of-phase 1 FDA package accepted and positive PRIME Phase 1b safety data. |
| Nov 06 | Earnings and cash | Negative | -2.9% | Q3 2025 results with net losses and going concern context despite higher cash. |
Recent fundamentally positive clinical and regulatory updates for Gemini have often seen flat or negative next-day price reactions, while more routine corporate actions show limited impact.
Over the past few months, Revelation Biosciences has advanced Gemini through early development, including an accepted end-of-phase 1 FDA package and PRIME study results showing safety and inflammatory reductions. The company initiated GMP manufacturing to support later-stage trials and reported Q3 2025 financials with ongoing net losses but additional cash from warrant activity. Corporate actions included a Special Meeting quorum and inducement equity grants. Today’s conference presentation of additional PRIME data fits into this ongoing effort to position Gemini for later-stage clinical development.
Regulatory & Risk Context
An amended Form S-3/A filed on 2025-09-29 registers shares issuable upon exercise of Class I warrants at $2.20 per share. The company would receive up to $28,743,000 in gross proceeds if all registered warrants are exercised for cash; the prospectus covers selling stockholders, with 4.99% and 9.99% beneficial ownership limits.
Market Pulse Summary
This announcement highlights upcoming presentation of additional PRIME clinical data for Gemini in CKD and AKI at AKI & CRRT 2026, emphasizing normalization of hyperinflammatory states and restored immunocompetence. It follows prior milestones such as FDA end-of-phase 1 engagement and GMP manufacturing initiation for later-stage trials. Investors may watch for detailed efficacy and safety metrics, regulatory feedback, and any updates on financing capacity, including warrant-related proceeds of up to $28,743,000, as Gemini moves toward larger studies.
Key Terms
acute kidney injury medical
chronic kidney disease medical
toll-like receptor 4 agonist medical
innate immune response medical
hyperinflammatory state medical
immunocompetence medical
AI-generated analysis. Not financial advice.
- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study -
SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced today that new clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) taking place in San Diego (March 29 - April 1, 2026). Presented data demonstrates normalization of the hyperinflammatory state in stage 3 and 4 CKD patients and restoration of immunocompetence. Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide, a toll-like receptor 4 agonist, in development for the treatment of acute and chronic inflammation-driven diseases such as AKI and CKD.
Title: Gemini restores normal innate immune response in CKD patients
Presenter: Robin Marsden, Senior Vice President of Biology, Revelation Biosciences
Date/Time: Sunday, March 29, 2026 5:30 p.m. -7:30 p.m. Pacific Time
Location: Manchester Grand Hyatt, 1 Market Place, San Diego CA
"We are pleased to have an opportunity to share our exciting clinical data for the treatment of CKD and AKI in this forum," said James Rolke, Chief Executive Officer of Revelation. "This interaction with key opinion leaders and health care providers treating AKI is another important step in our strategy to begin impactful later stage clinical studies."
About Gemini
Gemini is the Company's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEMINI-AKI program). Gemini is also being developed as a treatment for chronic kidney disease (GEMINI-CKD program), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI) and as a treatment to prevent post-surgical infection (GEMINI-PSI program). The potential of Gemini has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two phase 1 clinical studies. See additional detail here.
About AKI
Acute Kidney Injury or AKI, also known as acute renal failure, is defined as a rapid loss of kidney function. AKI causes a build-up of waste products in blood and makes it more difficult for kidneys to maintain the correct balance of fluid in the body. AKI can also significantly impact other organs such as the brain, heart, and lungs. Severe AKI requiring dialysis significantly increases the likelihood of worse outcomes including longer time in an ICU, potential to develop chronic kidney disease, and death.
AKI is a major cause of morbidity and mortality, affecting more than
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management's expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation's product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation's balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.
Company Contact
Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire
FAQ
What will Revelation Biosciences (REVB) present at AKI & CRRT 2026 on March 29, 2026?
When and where is Revelation's REVB presentation at AKI & CRRT 2026?
Who is presenting Revelation's Gemini data for REVB at the conference?
What patient population does Revelation's Gemini data reported at AKI & CRRT 2026 cover?
What clinical study supplied the data Revelation (REVB) will share at AKI & CRRT 2026?
How might the REVB Gemini presentation affect future clinical development?
